September 21st 2023
In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.
September 8th 2023
The State of the Targeted Therapy Landscape for CLL
July 26th 2023In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.
Read More
Watch and Wait Remains the Standard in Inactive Early-Stage CLL
June 11th 2023A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.
Read More
Venetoclax and Obinutuzumab With/Without Ibrutinib Improves Efficacy in CLL
May 17th 2023Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy
Read More
Comparison of BTK Inhibitors Shows Promising Results for Zanubrutinib Over Ibrutinib in CLL/SLL
February 14th 2023An interim analysis of the phase 3 ALPINE study showed stronger results for patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma on the next generation BTK inhibitor zanubrutinib than standard of care ibrutinib.
Read More